| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be3928f66bb2545a8175c61c56146b9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_21e5c29b56e36a9233bc57ee10efe048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9b3ec45e62175277459ff8c2be490f82 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4188
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2004-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc63ff0b84b23b5d2eb36866cf737593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b66f13ecb55ca70fb49814f2539152b9 |
| publicationDate |
2004-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2004110488-A1 |
| titleOfInvention |
Drug for overcoming anticancer agent resistance and method of screening the same |
| abstract |
A resistance overcoming agent capable of overcoming the resistance to anticancer agents. In particular, an overcoming agent for anticancer agent resistance, comprising an AR inhibiting compound as an active ingredient; use of an AR inhibiting compound for production of an anticancer agent resistance overcoming agent; a pharmaceutical composition comprising an AR inhibiting compound and an anticancer activity having compound; a method of screening an overcoming agent for anticancer agent resistance, comprising assessing a compound having AR inhibiting activity by means of an evaluation system for anticancer agent resistance overcoming to thereby select a highly effective compound; a method of treating resistant cancer through administration of an AR inhibitor combined with an anticancer agent to a patient; etc. Fidarestat is preferably used as the AR inhibiting compound. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11518748-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3226859-A4
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11351155-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103063794-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103063794-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11426386-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011092566-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11576900-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106362153-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008255217-A1 |
| priorityDate |
2003-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |